It can cost $75,000 to $250,000, and the names keep getting stranger as companies balance regulator concerns with the desire to market the product.» Read More
Trading was mixed in Asia on Wednesday, as sentiment turned cautious amid concerns over the health of Japan - the world's third largest economy - and ahead of the release of the U.S. Federal Reserves' meeting minutes.
"Mad Money" host Jim Cramer issues a warning investors should heed.
Jim Cramer just can't make sense of what's happening in the market. Why does it keep going higher? Is it time to stop questioning and jump in?
Stocks rose on Tuesday, lifting the Dow and S&P 500 to their loftiest ever.
Some of Tuesday midday movers:
CNBC's David Faber reports investor Bill Ackman has told CNBC he will withdraw from the special meeting on December 18th where Actavis shareholders could have voted on new directors.
Heads he wins. Tails he wins. That was the situation Bill Ackman found himself in — or perhaps more accurately, orchestrated — on Monday.
Deals worth $100 billion on Monday put the Street on pace for a year rivaling the dot-com bubble era and the private equity surge just before the financial crisis.
Hedge funds flocked to Apple ahead of launch of the iPhone 6, but the company is now the most sold position among some of world's largest funds.
Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.
Wall Street research was ready to give up, but "Mad Money" host Jim Cramer thinks this could be the start of a major turnaround.
Jim Cramer reviews the acquisition of Allergan by Actavis to judge just how lucrative the deal could really be for shareholders.
Stocks fell Monday after data had Japan unexpectedly falling into a recession.
Actavis announced it will acquire Allergan for $66 billion. Marc LoPresti of Lopresti Law Group, and Michael Farr of Farr, Miller & Washington, discuss Pershing Square Bill Ackman's actions.
Some of Monday's midday movers:
Actavis is buying Allergan for $66 billion. CNBC's Kate Kelly provides insight to speculation surrounding the benefit of the deal to Pershing Square's Bill Ackman.
The deal beats the unsolicited bid last spring of above $50 billion from Valeant, which teamed with Bill Ackman.
Allergan chairman & CEO David Pyott, explains why Allergan never engaged Valeant Pharmaceuticals and what's next for the newly combined companies.
CNBC's Jim Cramer speaks to Brent Saunders, Actavis CEO, and David Pyott, Allergan chairman & CEO, about the growth and R&D budget of the combined companies going forward.
CNBC's David Faber speaks to David Pyott, Allergan chairman & CEO, and Brent Saunders, Actavis CEO about their deal worth roughly $66 billion and what it means for shareholders.